Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2

Status

Recruiting 6Completed 4Active not recruiting 3Terminated 1Enrolling by invitation 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 71Gastrointestinal 43Head & Neck 30Breast 25Genitourinary 19Other solid neoplasm 17Gynecologic 17Sarcoma 10Lymphoid 9Dermatologic 6Tumor-Agnostic 4CNS 4Plasma cell 3Other hematologic neoplasm 2Endocrine 2NET 1Myeloid 1

Conditions

Neoplasms 3Neoplasm Metastasis 1

Interventions

Paclitaxel 57Gemcitabine 51Carboplatin 51Surveys and Questionnaires 48Docetaxel 37Bevacizumab 37pembrolizumab 33Nivolumab 29Cisplatin 28Fluorouracil 24Capecitabine 23Irinotecan 22Erlotinib Hydrochloride 22Sorafenib 20Leucovorin 19Afatinib 19Radiotherapy 18Pemetrexed 18Oxaliplatin 17Trastuzumab 16Ipilimumab 15regorafenib 14Blood Specimen Collection 14130-nm albumin-bound paclitaxel 14olaparib 13Interviews as Topic 13Cetuximab 13Albumin-Bound Paclitaxel 13atezolizumab 12Sunitinib 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Completed × durvalumab × Tumor-Agnostic × Clear all
NCT03406650 2025-05-04

SAKK 06/17

Swiss Cancer Institute

Phase 2 Completed
61 enrolled
Tumor-Agnostic

Neoplasms

NCT03946800 2024-10-02

A Study of MEDI1191 in Sequential and Concurrent Combination With Durvalumab in Subjects With Advanced Solid Tumors

MedImmune LLC

Phase 1 Completed
61 enrolled
Tumor-Agnostic

Neoplasms

NCT03094286 2024-06-24

Durvalumab in HIV-1 Patients With Solid Tumors

Spanish Lung Cancer Group

Phase 2 Completed
20 enrolled 36 charts
Tumor-Agnostic

Neoplasms

NCT03238027 2024-05-17

A Phase 1 Study to Investigate Axatilimab Alone or in Combination With Durvalumab in Patients With Solid Tumors

Syndax Pharmaceuticals

Phase 1 Completed
45 enrolled
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡